Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 8/20 | 0.57 |
| ▸ | NPC1 | O15118 | 6/20 | 0.57 |
| ▸ | MAPT | P10636 | 6/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.53 |
| ▸ | GAA | P10253 | 3/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | MMP1 | P03956 | 1/20 | 0.46 |
| ▸ | MMP13 | P45452 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL16058108 | 0.98 | RAB9A (0.60) | RAB9ANPC1MAPTALDH1A1MEN1 | |
| Hydrochloric Acid SCHEMBL28056839 | 0.88 | RAB9A (0.48) | RAB9ANPC1MAPTALDH1A1MEN1 | |
| SCHEMBL2838509 | 0.86 | RAB9A (0.62) | RAB9ANPC1MAPTALDH1A1MEN1 | |
| SCHEMBL10426673 | 0.84 | RAB9A (0.54) | RAB9ANPC1MAPTALDH1A1MEN1 | |
| SCHEMBL8053670 | 0.84 | SMN1; SMN2 (0.60) | RAB9ANPC1MAPTALDH1A1MEN1 | |
| SCHEMBL1246735 | 0.84 | RAB9A (0.64) | RAB9ANPC1MAPTALDH1A1MEN1 | |
| SCHEMBL22458203 | 0.83 | RAB9A (0.52) | RAB9ANPC1MAPTALDH1A1MEN1 | |
| SCHEMBL2842688 | 0.83 | RAB9A (0.52) | RAB9ANPC1MAPTALDH1A1MEN1 | |
| SCHEMBL2838513 | 0.83 | RAB9A (0.62) | RAB9ANPC1MAPTALDH1A1MEN1 | |
| SCHEMBL28056840 | 0.82 | NPC1 (0.40) | RAB9ANPC1MAPTALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3998260-B1 | SGC STIMULATORS | CYCLERION THERAPEUTICS INC (US) | 2023-11-01 | — | — | EP | disclosed |
| EP-3998260-B1 | SGC STIMULATORS | CYCLERION THERAPEUTICS INC (US) | 2023-11-01 | — | — | EP | disclosed |
| CN-109369635-B | Compound or pharmaceutically acceptable salt thereof, application thereof and pharmaceutical composition | 赛克里翁治疗有限公司 | 2023-06-30 | — | — | CN | disclosed |
| US-20230106002-A1 | sGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. | 2023-04-06 | — | — | US | disclosed |
| CN-109384778-B | Use of a compound or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of a disease, health condition or disorder | 赛克里翁治疗有限公司 | 2022-12-13 | — | — | CN | disclosed |
| CN-110016020-B | Compound or pharmaceutically acceptable salt thereof, application and pharmaceutical composition thereof | 赛克里翁治疗有限公司 | 2022-07-26 | — | — | CN | disclosed |
| EP-3998260-A1 | SGC STIMULATORS | Cyclerion Therapeutics, Inc. (US) | 2022-05-18 | — | — | EP | disclosed |
| EP-3998260-A1 | SGC STIMULATORS | Cyclerion Therapeutics, Inc. (US) | 2022-05-18 | — | — | EP | disclosed |
| EP-3660013-B1 | SGC STIMULATORS | CYCLERION THERAPEUTICS INC (US) | 2022-01-19 | — | — | EP | disclosed |
| EP-3660013-B1 | SGC STIMULATORS | CYCLERION THERAPEUTICS INC (US) | 2022-01-19 | — | — | EP | disclosed |
| US-20080255109-A1 | Non-peptide GnRH antagonists | VANTIA, LTD | 2008-10-16 | — | — | US | disclosed |
| US-20080255109-A1 | Non-peptide GnRH antagonists | VANTIA, LTD | 2008-10-16 | — | — | US | disclosed |
| US-20080255109-A1 | Non-peptide GnRH antagonists | VANTIA, LTD | 2008-10-16 | — | — | US | disclosed |
| US-7365065-B2 | Non-peptide GnRH antagonists | FERRING B.V. (NL) | 2008-04-29 | — | — | US | disclosed |
| US-7365065-B2 | Non-peptide GnRH antagonists | FERRING B.V. (NL) | 2008-04-29 | — | — | US | disclosed |
| US-7365065-B2 | Non-peptide GnRH antagonists | FERRING B.V. (NL) | 2008-04-29 | — | — | US | disclosed |
| US-20050222139-A1 | Non-peptide gnrh antagonists | FERRING B.V. (NL) | 2005-10-06 | — | — | US | disclosed |
| CN-1642917-A | Non-peptide GnRH antagonists | FERRING BV (NL) | 2005-07-20 | — | — | CN | disclosed |
| EP-1485356-A1 | NON-PEPTIDE GnRH ANTAGONISTS | Ferring BV (NL) | 2004-12-15 | — | — | EP | disclosed |
| WO-2003078398-A1 | NON-PEPTIDE GnRH ANTAGONISTS | FERRING BV (NL) | 2003-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222139-A1 | Non-peptide gnrh antagonists | GNRHR, BRS3, FSHR | RAB9A 4025/4885NPC1 2556/4885MAPT 4798/4885 |
| US-20230106002-A1 | sGC STIMULATORS | PTGIS, CGAS, GUCY1A1 | RAB9A 2090/4885NPC1 2841/4885MAPT 4849/4885 |
| US-20080255109-A1 | Non-peptide GnRH antagonists | GNRHR, BRS3, FSHR | RAB9A 3891/4885NPC1 2560/4885MAPT 4777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.